anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer

临床试验

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

计划入组 202 人 · 首次发布于 2022 年 4 月 22 日

已完成

NCT04351334

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

计划入组 1 人 · 首次发布于 2020 年 4 月 17 日

招募中

PER-001-17

XALT3: PHASE 3 RANDOMIZED STUDY COMPARING X-396 TO CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

计划入组 2 人

药物

查看全部 6778 →

Small Molecule

Approved

Ceritinib(Zykadia)

相关疾病：Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer

C₂₈H₃₆ClN₅O₃S · Rx

Small Molecule

Approved

Brigatinib(Alunbrig)

相关疾病：Metastatic Non-Small Cell Lung Cancer

C₂₉H₃₉ClN₇O₂P · Rx

Small Molecule

Approved

lorlatinib(Lorbrena, Lorviqua)

相关疾病：Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer

C₂₁H₁₉FN₆O₂ · Rx

机构

查看全部 1194 →

Summit Therapeutics Inc.

United States

Vaccinex

United States

IGM Biosciences

United States

资讯

查看全部 21207 →

去年

Estimand Framework Enhances Analysis of Patient-Reported Outcomes in Lung Cancer Trials

5个月前

Xuanzhu Biopharma's DiLuoAke Demonstrates Superior Efficacy Over Crizotinib in Phase III ALK-Positive NSCLC Trial

去年

临床试验

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

XALT3: PHASE 3 RANDOMIZED STUDY COMPARING X-396 TO CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

药物

Ceritinib(Zykadia)

Brigatinib(Alunbrig)

lorlatinib(Lorbrena, Lorviqua)

机构

Summit Therapeutics Inc.

Vaccinex

IGM Biosciences

资讯

Estimand Framework Enhances Analysis of Patient-Reported Outcomes in Lung Cancer Trials

Xuanzhu Biopharma's DiLuoAke Demonstrates Superior Efficacy Over Crizotinib in Phase III ALK-Positive NSCLC Trial

Significant Weight Gain Underreported in ALK+ Lung Cancer Patients on Alecensa Treatment